AbbVie Beats Q1 Estimates on Strong Skyrizi, Rinvoq Sales

Key Highlights

AbbVie announced first-quarter revenue and profit that surpassed Wall Street expectations, driven by strong commercial success from its newer immunology drugs, Skyrizi and Rinvoq. The company reported quarterly revenue of $15 billion and adjusted earnings of $2.65 per share, exceeding analyst forecasts.

Following the strong performance, AbbVie raised its full-year adjusted earnings guidance to a new range of $14.08 to $14.28 per share, signaling confidence in its continued growth trajectory.

Market Performance Overview

The results highlight AbbVie's successful transition away from its former blockbuster drug, Humira, which faces competition from cheaper biosimilars. Skyrizi sales grew 30.9% to $4.48 billion, while Rinvoq sales increased 23.3% to $2.12 billion, with both drugs beating estimates.

In contrast, global Humira sales fell by 38.6% to $688 million. The company's neuroscience portfolio also showed strength, with Global Botox Therapeutic sales exceeding the $1 billion quarterly mark for the first time.

Impact on Market Outlook

AbbVie's ability to offset Humira's revenue decline with its newer drug portfolio strengthens investor confidence. The continued momentum of Skyrizi and Rinvoq is crucial for the company's long-term strategy and market position in the pharmaceutical industry.

Summary

The positive quarterly report and upgraded forecast indicate a robust outlook for AbbVie. The company is effectively managing the patent cliff for Humira through the successful execution and growth of its newer key assets.

FAQ

Q: Which drugs drove AbbVie's Q1 2024 growth?
A: Skyrizi and Rinvoq were the primary growth drivers, with combined sales exceeding $6.6 billion, successfully offsetting the revenue decline from Humira.

Q: Did AbbVie update its financial forecast for the year?
A: Yes, AbbVie raised its full-year adjusted earnings per share forecast to a new range of $14.08 to $14.28.

Source: Investing.com